With strategic expansion plans, Dr. Reddy’s Laboratories Ltd. has entered into collaboration with Amgen- an independent biotechnology company. As a part of collaboration, Dr. Reddy’s will market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis and will commercialize XGEVA(denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.
In 2015, Dr. Reddy’s announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen’s Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India.
The collaboration aims to leverage the capabilities of both the companies, combining Amgen’s innovative therapies with Dr. Reddy’s deep understanding of patient and physician needs in India.
M.V. Ramana, Executive Vice President and Head of Emerging markets and India Business, Dr Reddy’s Laboratories Limited said, “We are delighted to continue our relationship with Amgen as it strengthens our constant endeavor to enhance patient’s access to novel treatment options across therapy areas. These medicines provide unique treatment options to physicians to address unmet medical need in the area of oncology and osteoporosis.”
Penny Wan, Amgen Vice President and General Manager, Japan Asia Pacific Region said,”We are happy to strengthen our relationship with Dr Reddy’s. Amgen is committed to addressing unmet medical needs of patients in India, and we are pleased with the commitment Dr Reddy’s has demonstrated toward making our medicines available in India as quickly as possible.”
XGEVA is a RANK ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone.
Vectibix is an epidermal growth factor receptor (EGFR) antagonist approved in India for the treatment of adult patients with wild-type KRAS metastatic colorectal cancer (m-CRC) as first line treatment as monotherapy following disease progression, in wild type RAS m-CRC as first-line combination with FOLFOX and in second line in combination with FOLFIRI after prior treatment with fluoropyrimidine-based chemotherapy (excluding irinotecan).
Prolia is a RANK ligand (RANKL) inhibitor approved in India for treatment of post-menopausal women with osteoporosis at high risk for fracture and also for treatment of increased bone mass in men with osteoporosis. Often referred to as the “silent epidemic,” osteoporosis is a global problem that is increasing in significance as the population of the world both increases and ages. The World Health Organization (WHO) has recently identified osteoporosis as a priority health issue along with other major non-communicable diseases.